Hantavirus Science Markets

Science markets resolve against ClinicalTrials.gov registrations, FDA / EMA approval announcements, GISAID and GenBank deposit timestamps, and DOI-anchored peer-reviewed publications in journals such as NEJM, Lancet ID, Nature Medicine and Emerging Infectious Diseases.

• Will WHO formally acknowledge sustained human-to-human Andes transmission in 2026?

  closes in 231d 21h· transmission· science
  yes

  11¢
• Will an Andes/HPS vaccine candidate enter Phase 2 trials in 2026?

  closes in 231d 21h· vaccine· Phase 2
  yes

  41¢
• Will WHO assign a Greek-letter (or successor scheme) variant name to a hantavirus lineage in 2026?

  closes in 231d 21h· variant· naming· covid-echo
  yes

  8¢
• Will any regulator grant emergency authorization to a hantavirus vaccine in 2026?

  closes in 231d 21h· vaccine· EUA· covid-echo
  yes

  5¢
• Will a 'lab-origin' hypothesis appear in any G7 intelligence or government statement on hantavirus by Dec 31?

  closes in 231d 21h· origin· lab-leak· covid-echo
  yes

  13¢
• Will a peer-reviewed paper confirm a hantavirus reinfection case in 2026?

  closes in 231d 21h· reinfection· immunology· covid-echo
  yes

  9¢
• Will WHO, NIH, or NICE formally recognize a 'post-hantavirus' chronic syndrome by Dec 31?

  closes in 231d 21h· long-hanta· chronic· covid-echo
  yes

  6¢
• Will Moderna's hantavirus vaccine mRNA-1080 enter Phase 2 by December 31?

  closes in 231d 21h· Moderna· vaccine· mRNA
  yes

  22¢
• Will any hantavirus vaccine receive Emergency Use Authorization by March 2027?

  closes in 321d 21h· vaccine· EUA· hantavirus
  yes

  8¢
• Will a hantavirus antiviral treatment be approved by December 31, 2026?

  closes in 231d 21h· antiviral· treatment· hantavirus
  yes

  10¢
• Will Regeneron's hantavirus monoclonal antibody enter Phase 2 by October 1?

  closes in 140d 21h· Regeneron· monoclonal-antibody· hantavirus
  yes

  16¢